George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
|Articles|September 16, 2008
- April15 2003
- Volume 10
- Issue 7
THE 50% CREDIT FLAG
Author(s)Michael Sheehan
Advertisement
Most lenders get leery when theysee credit card accounts or homeequity loans on your credit reportwith balances that are more than50% of the account limit. To avoidgetting tagged as a poorer credit riskthan you really are, ask your cardissuer to raise the limit on theaccount. If that doesn't work, thinkabout putting part of the debt onanother card. Be careful with the latteroption, though; lenders also don'tlike to see a lot of new applicationsfor credit cards on your report andwill downgrade you as a credit risk ifthey see too many.
Articles in this issue
about 18 years ago
Secure Tomorrow, Don't Lose Todayabout 18 years ago
Avoid the Turmoil of Insurance Mistakesabout 18 years ago
Bulletproof Your Car from the IRS' Aimabout 18 years ago
The PMD Answerman Q & Aabout 18 years ago
Impart Financial Values to Your Childrenabout 18 years ago
Watch Your Nest Egg's Financial Healthabout 18 years ago
Invest Some Land in Your 401(k) Accountabout 18 years ago
Plan According to Social Security Rulesabout 18 years ago
Discover Another Defined-Benefit Avenueabout 18 years ago
Know All Your Estate Planning BenefitsAdvertisement
Related to this article
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
The FDA-approved update adds phase 3 HYPERION data on adults diagnosed with PAH within the past year.
Josh Woolley, MD, PhD, explains why current active placebos fail to mask high-dose psilocybin trials and outlines a framework proposed to fix it.
Raj Chovatiya, MD, PhD, on zasocitinib results in the scalp, nails, palms and soles, speed of response and once-daily oral dosing in psoriasis.
Advertisement
Advertisement
Trending on HCPLive
1
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
2
FAQ: What the Expanded Marstacimab Approval Means for Hemophilia A, B
3
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
4
EMBARQ-CSU: Barzolvolimab Meets Primary, Secondary Endpoints in CSU Trials
5